Document Detail

Opportunities for Targeting the Angiotensin-Converting Enzyme 2/Angiotensin-(1-7)/Mas Receptor Pathway in Hypertension.
MedLine Citation:
PMID:  23212695     Owner:  NLM     Status:  Publisher    
It is well known that the renin-angiotensin system (RAS) plays a pivotal role in the pathophysiology of cardiovascular diseases. This is well illustrated by the great success of ACE inhibitors and angiotensin (Ang) II AT(1) blockers in the treatment of hypertension and its complications. In the past decade, the classical concept of RAS orchestrated by a series of enzymatic reactions culminating in the linear generation and action of Ang II has expanded and become more complex. From the discoveries of new components such as the angiotensin converting enzyme 2 and the receptor Mas emerged a novel concept of dual opposite branches of the RAS: one vasoconstrictor and pro-hypertensive composed of ACE/Ang II/AT1; and other vasodilator and anti-hypertensive composed of ACE2/Ang-(1-7)/Mas. In this review we will discuss recent findings concerning the biological role of the ACE2/Ang-(1-7)/Mas arm in the cardiovascular system and highlight the initiatives to develop potential therapeutic strategies based on this axis for treating hypertension.
Rodrigo Araujo Fraga-Silva; Anderson Jose Ferreira; Robson Augusto Souza Dos Santos
Related Documents :
7944025 - Cardiorespiratory effects of glycopyrrolate-butorphanol-xylazine combination, with and ...
663385 - Exerimental evaluation of antianginal drugs.
8685755 - Improvement in oxygenation after large volume paracentesis.
22260125 - On quantifying nonthermal effects on the lethality of pressure-assisted heat preservati...
16685205 - Functional variants of the angiotensinogen gene determine antihypertensive responses to...
21726655 - Effect of non-thermal processing by high hydrostatic pressure on the survival of probio...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-5
Journal Detail:
Title:  Current hypertension reports     Volume:  -     ISSN:  1534-3111     ISO Abbreviation:  Curr. Hypertens. Rep.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100888982     Medline TA:  Curr Hypertens Rep     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
National Institute of Science and Technology in Nanobiopharmaceutics, Belo Horizonte, MG, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Long-term self-reported treatment effects and experience of radiofrequency-induced thermotherapy of ...